
Annual report 2021
added 12-23-2023
Amryt Pharma plc Market Cap 2011-2026 | AMYT
As of March 06, 2026 Amryt Pharma plc has a market cap of $ 621 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.55 B | 449 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.55 B | 449 M | 1.5 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
ADMA Biologics
ADMA
|
3.78 B | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Anika Therapeutics
ANIK
|
373 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
ANI Pharmaceuticals
ANIP
|
1.2 B | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
AVEO Pharmaceuticals
AVEO
|
98 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
13.1 B | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.72 | -3.31 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 8.26 | -1.31 % | $ 1.36 B | ||
|
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | ||
|
Codexis
CDXS
|
291 M | $ 1.25 | 16.2 % | $ 91.8 M | ||
|
Cabaletta Bio
CABA
|
20.5 M | $ 3.2 | -6.71 % | $ 3.74 M | ||
|
Coherus BioSciences
CHRS
|
209 M | $ 1.76 | -0.28 % | $ 166 M | ||
|
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
231 M | - | -7.23 % | $ 13 M |